Recap: AAM’s FallTech Conference 2017 | Association for Accessible Medicines
AAM Statement - President Trump’s Blueprint to Lower Drug Prices
FallTech 2017 - State of the Industry Address from AAM CEO Chester “Chip” Davis, Jr.

Recap: AAM’s FallTech Conference 2017

AAM’s Fall Tech Conference November 6 and 7 focused on Abbreviated New Drug Application (ANDA) review, GDUFA II enhancements, drug pricing, bioequivalence and data integrity were the main topics of AAM’s Fall Tech Conference. As you read this event recap of the educational conference, start looking ahead to our next annual Access! conference, February 12-14, 2018, in Orlando, FL.

View Instagram Photos

View Facebook Album

The Fall Tech Conference brought together industry leaders and decision makers, including FDA Commissioner Scott Gottlieb, M.D., who outlined the Drug Competition Action Plan and declared,

“I think this is a win-win. What’s good for the generic drug industry and policies we are trying to craft is especially good for consumers.”

Keynote Address by FDA Commissioner Scott Gottlieb, M.D.

Other FDA presenters included:

  • Kathleen Uhl, M.D., Director, Office of Generic Drugs
  • Giuseppe Randazzo, MS, Director, Office of Program and Regulatory Operations, Office of Pharmaceutical Quality
  • Ellen Morrison, Assistant Commissioner, Medical Products and Tobacco Operations, Office of Regulatory Affairs

AAM President and CEO Chester “Chip” Davis, Jr. delivered a State of the Industry Address, highlighting the progress being made toward the goal of prescription drug accessibility while recognizing threats from well-intentioned but misguided legislation and anti-competitive practices from some brand-name drug companies.

A panel on International Regulatory Harmonization, moderated by AAM’s David Gaugh, featured:

AAM’s Craig Burton moderated a panel on Rising Drug Prices: Opportunities for Generics, featuring:

“Driving Competition to Improve Lives” is the theme of AAM's annual meeting: Access! 2018. Register today!

Register Now

 

Erica Klinger


By Erica Klinger, AAM Marketing Director

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.